{"id":935383,"date":"2026-02-09T17:34:12","date_gmt":"2026-02-09T22:34:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-guggenheim-securities-emerging-outlook-biotech-summit\/"},"modified":"2026-02-09T17:34:12","modified_gmt":"2026-02-09T22:34:12","slug":"dbv-technologies-to-participate-in-the-guggenheim-securities-emerging-outlook-biotech-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-guggenheim-securities-emerging-outlook-biotech-summit\/","title":{"rendered":"DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit"},"content":{"rendered":"
\n

Ch\u00e2tillon, France, February 9, 2025<\/p>\n

\n DBV Technologies to <\/b>
\n Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit<\/b>\n <\/p>\n

DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT) (the \u201cCompany<\/b>\u201d), a late-stage biopharmaceutical company, today announced Daniel Tass\u00e9, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit which is being held February 11-12, 2026 in New York, NY. Mr. Tass\u00e9\u2019s presentation is scheduled for Thursday, February 12, at 2:30pm ET.<\/p>\n

A live webcast of the fireside chat can be accessed here<\/a> and will also be available on the Events section of the Company\u2019s Investors website: https:\/\/dbv-technologies.com\/investor-overview\/events\/<\/a><\/p>\n

A replay will be available on DBV Technologies\u2019 website for 90 days after the event.<\/p>\n

\n About DBV Technologies<\/b>
\n
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN\u00ae patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN\u00ae patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual\u2019s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin\u2019s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company\u2019s food allergy programs include ongoing clinical trials of VIASKIN\u00ae Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).<\/p>\n

DBV Technologies is headquartered in Ch\u00e2tillon, France, with North American operations in Warren, NJ. The Company\u2019s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company\u2019s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT \u2013 CUSIP: 23306J309). For more information, please visit www.dbv-technologies.com<\/a> and engage with us on X (formerly Twitter)<\/a> and LinkedIn<\/a>. <\/p>\n

VIASKIN is a registered trademark of DBV Technologies.<\/p>\n

\n Investor Contact <\/b>
\n
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com<\/a><\/p>\n

\n Media Contact<\/b>
\n
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com<\/a><\/p>\n

\n Attachment<\/strong>\n <\/p>\n